🌍·Sep 13, 2021Industry
New study in pediatric epilepsy supports the value of early genetic testing as a tool for making an accurate and an early diagnosis in children
Publisher
B
Blueprint Genetics (Quest Diagnostics)
Finland/USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Blueprint Genetics (Quest Diagnostics)
- Region
- Finland/USA
- Scope
- Industry
- Published
- September 13, 2021
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on blueprintgenetics.com
Leave the platform to read the original full article on the publisher site.
Source: Blueprint Genetics (Quest Diagnostics)
Scope: Industry
Related coverage
More related coverage
SELLAS Life Sciences·22h ago
Company - Sellas Life Sciences
Hyman, Phelps & McNamara (FDA Law)·23h ago
WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage
Sumitomo Pharma·1d ago
Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia
Menicon·1d ago